Dr. Reddys Laboratories Ltd.

Dr. Reddy’s Laboratories is currently trading at Rs. 2619.00, up by 10.30 points or 0.39% from its previous closing of Rs. 2608.70 on the BSE.

The scrip opened at Rs. 2616.00 and has touched a high and low of Rs. 2623.75 and Rs. 2615.95 respectively.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3689.00 on 20-Jul-2016 and a 52 week low of Rs. 2560.00 on 22-Mar-2017.

Last one week high and low of the scrip stood at Rs. 2721.95 and Rs. 2606.00 respectively. The current market cap of the company is Rs. 43,390.00 crore.

The promoters holding in the company stood at 26.79%, while Institutions and Non-Institutions held 42.95% and 13.87% respectively.

Dr. Reddy’s Laboratories has launched Progesterone Capsules, 100 mg and 200 mg, a therapeutic equivalent generic version of Prometrium (Progesterone) Capsules in the United States market, approved by the U.S. Food and Drug Administration (USFDA).

The company’s Progesterone Capsules, 100 mg and 200 mg, are available in bottle count size of 100. Prometrium is a registered trademark of ABBVIE Products LLC.

The Prometrium brand and generic had US sales of around $153 million MAT for the most recent twelve months ending in February 2017.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.